Protalix BioTherapeutics (PLX) Cash from Discontinued Operations (2015 - 2017)
Protalix BioTherapeutics (PLX) posted quarterly Cash from Discontinued Operations of 2000.0 for Q3 2017, up 100.68% year-over-year from 996.63 in Q3 2016, and up 125.0% quarter-over-quarter from 8000.0 in Q2 2017.
Protalix BioTherapeutics (PLX) Cash from Discontinued Operations (2015 - 2017) Analysis & Trends
Protalix BioTherapeutics' Cash from Discontinued Operations history runs 3 years deep, the most recent figure standing at 2000.0 for Q3 2017.
- In Q3 2017, Cash from Discontinued Operations rose 100.68% year-over-year to 2000.0; the TTM figure through Sep 2017 stood at 116000.0 (down 97.19% YoY), while the FY2016 annual figure was 11000.0, down 100.74% from the prior year.
- Cash from Discontinued Operations for Q3 2017 stood at 2000.0, up from 8000.0 in the prior quarter.
- The five-year high for Cash from Discontinued Operations was 4138000.0 in Q4 2015, with the low at 1406000.0 in Q3 2015.
- The 3-year median for Cash from Discontinued Operations is 131000.0 (2015), against an average of 159100.0.
- The sharpest annual moves came in 2016 and 2017: Cash from Discontinued Operations jumped 164.72% in 2016, then tumbled 101.25% in 2017.
- Protalix BioTherapeutics' Cash from Discontinued Operations stood at 4138000.0 in 2015, then tumbled by 107.15% to 296000.0 in 2016, then surged by 100.68% to 2000.0 in 2017.
- Business Quant data shows PLX's Cash from Discontinued Operations at 2000.0 in Q3 2017, 8000.0 in Q2 2017, and 122000.0 in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 2,000.00 |
| Sep 30, 2017 | 2,000.00 |
| Jun 30, 2017 | -8,000.00 |
| Jun 30, 2017 | -8,000.00 |
| Mar 31, 2017 | 122,000.00 |
| Mar 31, 2017 | 122,000.00 |
| Sep 30, 2016 | -296,000.00 |
| Sep 30, 2016 | -296,000.00 |
| Jun 30, 2016 | 642,000.00 |
| Jun 30, 2016 | 642,000.00 |
| Mar 31, 2016 | -357,000.00 |
| Mar 31, 2016 | -357,000.00 |
| Dec 31, 2015 | 4.14 Mn |
| Dec 31, 2015 | 4.14 Mn |
| Sep 30, 2015 | -1.41 Mn |
| Sep 30, 2015 | -1.41 Mn |
| Jun 30, 2015 | -992,000.00 |
| Jun 30, 2015 | -992,000.00 |
| Mar 31, 2015 | -254,000.00 |
| Mar 31, 2015 | -254,000.00 |